Research programme: mRNA based antiviral vaccines and passive immunity therapeutics - Valera/Merck

Drug Profile

Research programme: mRNA based antiviral vaccines and passive immunity therapeutics - Valera/Merck

Alternative Names: mRNA 1566

Latest Information Update: 15 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valera LLC
  • Developer Merck & Co; Valera LLC
  • Class RNA; Vaccines
  • Mechanism of Action Immunostimulants; Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Viral infections

Most Recent Events

  • 11 Jan 2016 Merck in-licenses mRNA based vaccines from Moderna
  • 13 Jan 2015 Moderna Therapeutics, through its subsidiary Valera LLC and Merck & Co. agree to co-develop mRNA based vaccines and passive immunity therapeutics for Viral infections
  • 13 Jan 2015 Early research in Viral infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top